All News
Romosuzumab and Low Sclerostin Levels Underlie CV Risk
EurekAlert!
New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS.
Read Article
Pericarditis Management
On the final day of ACR 2023 State of the Art Conference, Dr. Paul Cremer reviewed pericarditis management. Dr. Cremer, a cardiologist at the Cleveland Clinic Foundation, reviewed the questions patients ask about pericarditis including why the disease develops, will it recur, how is it treated, and what will their treatment duration be.
Read Article
The Match Game (4.14.2023)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.
Read Article
Clinical Profile of RA-associated Interstitial Lung Disease
A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.
Read Article
JAKinib safety takeaways
- avoid in older population 65 yo, malignancy, CV risk, VTE risk
- appropriate in younger pts without VTE/CVD risk factors
#RNL2023 @RheumNow https://t.co/mFvvqJ9Jbp https://t.co/A76tR2S1Rb
Links:
Dr. John Cush RheumNow ( View Tweet)
Pericarditis Management
Dr. Cremer, a cardiologist at the Cleveland Clinic Foundation, reviewed the questions patients ask about pericarditis including why the disease develops, will it recur, how is it treated, and what will their treatment duration be.
https://t.co/EiK3YDzXvT https://t.co/MrS9WeYn0r
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of Steroids in hosp community-acquired pneumonia (CAP). 18 studies 4661 pts. Corticosteroids reduced mortality in more severe CAP (RR 0.62; 0.45 to 0.85), but not less severe CAP(RR 1.08). Steroids lower need for mech ventilation, ICU https://t.co/dj7zABqQ3r https://t.co/Mb4g7ICdX9
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jeff Sparks talks sex differences and rheumatoid arthritis associated interstitial lung disease.
https://t.co/asUrfXw2Y1 https://t.co/oLwi8BvquO
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical Profile of RA-associated Interstitial Lung Disease
A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.
https://t.co/FazEGcHh5H https://t.co/oh6oIpj21k
Links:
Dr. John Cush RheumNow ( View Tweet)
Japanese cohort study shows Lung cancer is more common in males w/ elder-onset dermatomyositis - risk increased by Smoking, anti-TIF1-γ-Abs and elevated MLR (monocyte to lymphocyte ratio) https://t.co/C7BTAV5gCj https://t.co/YGq6sUbLOh
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical Profile of RA-associated Interstitial Lung Disease
A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.
https://t.co/Khe9jV1jGa https://t.co/WejiaxolQP
Links:
Dr. John Cush RheumNow ( View Tweet)
Predictors of RA-ILD include smoking, Dz activity, steroid use and obesity. @jeffsparks @UTSW_Rheum https://t.co/VRQc9igHWW
Dr. John Cush RheumNow ( View Tweet)
Methotrexate-induced pneumonitis (0.3% risk) is different than RA-ILD. MTX does not increase odds of RA-ILD. @jeffsparks @UTSW_Rheum https://t.co/JV1CcB0sLP
Dr. John Cush RheumNow ( View Tweet)
Japanese cohort study shows Lung cancer is more common in males w/ elder-onset dermatomyositis - risk increased by Smoking, anti-TIF1-γ-Abs and elevated MLR (monocyte to lymphocyte ratio) https://t.co/LlTkiWp7pb https://t.co/Bu9atnI8je
Links:
Dr. John Cush RheumNow ( View Tweet)
Disease activity increases the risk of future RA-ILD. For every one point increase in DAS28, theres a 35% increase risk of RA-ILD @jeffsparks @UTSW_Rheum https://t.co/P3dNDVanuL
Dr. John Cush RheumNow ( View Tweet)
MUC5B is a common genetic variant (~12%) that is strongly assoc w/ IPF, but also RA-ILD (3.1-4.7 fold risk) @jeffsparks @UTSW_Rheum https://t.co/t1Kgmj8a3x
Dr. John Cush RheumNow ( View Tweet)
Survival in RA-ILD is reduced (data from two different eras) @jeffsparks @UTSW_Rheum https://t.co/7eGgGnEgwW
Dr. John Cush RheumNow ( View Tweet)
Risk of RA-ILD is 15% (or 1 in 6) according to Mayo clinic (Olmstead county) data. @jeffsparks https://t.co/KynitLCsK7
Dr. John Cush RheumNow ( View Tweet)
#RA with ILD portends poor outcomes, especially if seropositive. Visiting professor Dr. Jeff sparks @jeffsparks @UTSW_Rheum https://t.co/fbVyDMUm6L
Dr. John Cush RheumNow ( View Tweet)
Antiphospholipid Antibodies With Incident Cardiovascular Events
Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk?
https://t.co/XQk17P6D2f https://t.co/y5exrsicW8
Links:
Dr. John Cush RheumNow ( View Tweet)
